Pharmacotherapy of schizophrenia: a review.
Traditional antipsychotic medications have targeted the dopamine system. Yet, the isolation and cloning of multiple dopamine receptor subtypes and the recognition of non-dopaminergic pathways (for example, serotonin) in schizophrenia have led to the development of new pharmacological strategies in pharmacotherapy. The author summarizes recent biochemical and pharmacological data and the clinical experience with novel antischizophrenic compounds.
Sigmundson
H K
HK
Mental Health Services, Ministry of Health, Province of British Columbia.
D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001921:Brain / Q000187:drug effects / Q000503:physiopathology; D003024:Clozapine / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007555:Isoxazoles / Q000009:adverse effects / Q000627:therapeutic use; D010880:Piperidines / Q000009:adverse effects / Q000627:therapeutic use; D011569:Psychiatric Status Rating Scales; D011954:Receptors, Dopamine / Q000187:drug effects / Q000502:physiology; D011985:Receptors, Serotonin / Q000187:drug effects / Q000502:physiology; D018967:Risperidone; D012559:Schizophrenia / Q000188:drug therapy* / Q000503:physiopathology; D012565:Schizophrenic Psychology
D014150:Antipsychotic Agents; D007555:Isoxazoles; D010880:Piperidines; D011954:Receptors, Dopamine; D011985:Receptors, Serotonin; D003024:Clozapine; D018967:Risperidone